Modulation of the btla-hvem axis to enhance adoptive cell transfer immunotherapy
AssigneeThe Trustees of the University of Pennsylvania
InventorsMarco Ruella, Puneeth Guruprasad
Life of this patent
Estimating the term…
Abstract
The present disclosure provides an immune cell genetically modified to express a chimeric antigen receptor (CAR) or a T cell receptor (TCR), wherein the immune cell comprises altered signaling of B and T lymphocyte attenuator (BTLA) and/or herpes virus entry mediator (HVEM). Also provided are methods and uses of the immune cell for treating cancer. Related nucleic acids, vectors, and pharmaceutical compositions are also provided.
Claims26
An immune cell genetically modified to express a chimeric antigen receptor (CAR) or a T cell receptor (TCR), wherein the immune cell comprises altered signaling of B and T lymphocyte attenuator (BTLA) and/or herpes virus entry mediator (HVEM).
4-5. (canceled)
9-10. (canceled)
13-22. (canceled)
(canceled)
A method of treating cancer in a subject in need thereof, the method comprising administering to the subject a therapeutically effective amount of an immune cell genetically modified to express a chimeric antigen receptor (CAR) or a T cell receptor (TCR), wherein the immune cell comprises altered signaling of B and T lymphocyte attenuator (BTLA) and/or herpes virus entry mediator (HVEM).
28-29. (canceled)
33-34. (canceled)
37-46. (canceled)
Dependencies are inferred from the claim text.